Published in J Exp Med on November 17, 1997
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma | NCT00034554
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 3.06
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med (1998) 2.58
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med (2002) 2.20
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A (1999) 1.98
DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med (1999) 1.93
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A (1998) 1.81
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A (1998) 1.70
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev (2002) 1.61
Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med (2008) 1.61
Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest (2004) 1.57
Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol (2015) 1.57
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
Toll receptors: a central element in innate immune responses. Infect Immun (2002) 1.53
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun (2000) 1.48
DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med (1998) 1.41
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun (1999) 1.32
Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol (2008) 1.31
Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun (2004) 1.30
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J (2007) 1.29
Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev (2009) 1.28
Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine (2007) 1.28
Science, medicine, and the future. Allergic disorders. BMJ (2000) 1.27
Food allergy. J Clin Invest (2011) 1.27
Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med (2003) 1.24
DNA activates human immune cells through a CpG sequence-dependent manner. Immunology (1999) 1.23
IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med (2010) 1.23
Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med (1999) 1.22
CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol (2004) 1.22
Activation of human and chicken toll-like receptors by Campylobacter spp. Infect Immun (2009) 1.20
Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J Virol (2003) 1.20
Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun (2001) 1.19
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
Scrub typhus vaccine candidate Kp r56 induces humoral and cellular immune responses in cynomolgus monkeys. Infect Immun (2005) 1.16
CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun (2002) 1.16
CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol (1999) 1.14
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun (1999) 1.13
The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol (2002) 1.13
Strategies to alleviate original antigenic sin responses to influenza viruses. Proc Natl Acad Sci U S A (2012) 1.12
Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun (2002) 1.11
Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med (1997) 1.07
Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol (2001) 1.07
Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun (2006) 1.07
Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol (2002) 1.06
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine (2008) 1.05
Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res (2010) 1.05
Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun (2007) 1.05
CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun (2000) 1.05
Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect Immun (2002) 1.05
Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology (2014) 1.04
TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology (2004) 1.04
Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells. Infect Immun (2004) 1.03
Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology (2002) 1.03
Toll-like receptors differentially induce nucleosome remodelling at the IL-12p40 promoter. EMBO Rep (2004) 1.01
Recombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice. Infect Immun (2001) 1.00
Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response. Front Immunol (2013) 1.00
CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology (2000) 0.98
Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. Proc Natl Acad Sci U S A (2014) 0.98
Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology (2002) 0.97
The effects of DNA containing CpG motif on dendritic cells. Immunology (2000) 0.96
Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol (2011) 0.95
CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology (2004) 0.94
Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One (2012) 0.94
Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun (2004) 0.92
HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. Vaccine (2010) 0.92
Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice. Parasitol Res (2009) 0.92
Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Eur J Clin Microbiol Infect Dis (1998) 0.92
Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol (2003) 0.92
Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One (2011) 0.92
Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials (2010) 0.92
Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. Infect Immun (1999) 0.91
CXCL10 is critical for the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated dendritic cells. PLoS One (2012) 0.91
Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology (2001) 0.91
Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer (2003) 0.91
DNA vaccination favours memory rather than effector B cell responses. Clin Exp Immunol (1999) 0.91
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Clin Exp Immunol (2006) 0.90
Vibrio cholerae proteome-wide screen for immunostimulatory proteins identifies phosphatidylserine decarboxylase as a novel Toll-like receptor 4 agonist. PLoS Pathog (2009) 0.90
Food allergy: recent advances in pathophysiology and treatment. Allergy Asthma Immunol Res (2009) 0.90
A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J Gastroenterol (2004) 0.89
Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin (2009) 0.89
DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells. Infect Immun (1998) 0.89
Antitumor activity of G3139 lipid nanoparticles (LNPs). Mol Pharm (2009) 0.88
Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. Clin Vaccine Immunol (2009) 0.88
Electroporation advances in large animals. Curr Gene Ther (2009) 0.87
Development of a Chlamydia trachomatis T cell Vaccine. Hum Vaccin (2010) 0.87
Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect Immun (2000) 0.87
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med (1989) 11.36
Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol (1994) 8.43
The regulation of immunity to Leishmania major. Annu Rev Immunol (1995) 8.05
Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 7.93
Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med (1988) 7.02
Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med (1990) 6.35
Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med (1993) 5.75
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71
Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today (1995) 5.32
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 5.26
Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res (1988) 4.49
Induction of TH1 and TH2 immunity in neonatal mice. Science (1996) 4.25
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
T cell genetic background determines default T helper phenotype development in vitro. J Exp Med (1995) 3.18
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
Macrophages ingest and are activated by bacterial DNA. J Immunol (1996) 2.64
Th1 and Th2 subsets: paradigms lost? Immunol Today (1995) 2.21
Bacterial DNA causes septic shock. Nature (1997) 2.19
Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 2.06
Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol (1996) 2.02
Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol (1992) 2.02
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A (1996) 2.01
DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol (1992) 1.96
Immune activation by bacterial DNA: a new genetic code. Immunity (1996) 1.63
Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol (1995) 1.53
Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol (1997) 1.46
IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol (1996) 1.42
Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol (1992) 1.34
Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med (1995) 1.08
Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol (1996) 1.08
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des (1997) 1.01
In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev (1994) 0.97
B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 11.53
Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature (1993) 5.47
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 5.26
Induction of TH1 and TH2 immunity in neonatal mice. Science (1996) 4.25
Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23
Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature (1993) 4.19
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 3.64
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol (2001) 3.06
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 2.93
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 2.73
Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol (2000) 2.59
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A (1997) 2.35
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35
Why peptides? Their possible role in the evolution of MHC-restricted T-cell recognition. Immunol Today (1989) 2.23
Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J Immunol (1991) 2.08
Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med (1996) 2.06
Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 2.06
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A (1999) 1.98
Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol (1998) 1.97
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 1.94
Negative control region at the 5' end of murine leukemia virus long terminal repeats. Mol Cell Biol (1989) 1.88
Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages. Cell Immunol (2000) 1.84
Surfactant protein D enhances bacterial antigen presentation by bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol (2001) 1.78
CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest (1997) 1.71
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine (2004) 1.71
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A (1998) 1.70
Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med (1998) 1.70
Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol (1999) 1.66
In vivo competition between self peptides and foreign antigens in T-cell activation. Nature (1988) 1.66
Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 1.65
CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol (1998) 1.62
Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J Immunol (2000) 1.61
Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum (1999) 1.59
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A (1999) 1.59
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A (1988) 1.51
CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J Immunol (2001) 1.51
The phoP locus influences processing and presentation of Salmonella typhimurium antigens by activated macrophages. Mol Microbiol (1995) 1.50
Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol (1997) 1.46
Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol (1996) 1.46
Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol (2000) 1.43
The human immune system in hu-PBL-SCID mice. Immunol Today (1995) 1.40
CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine (1998) 1.35
A T cell clone's avidity is a function of its activation state. J Immunol (2001) 1.35
CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev (2001) 1.34
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 1.34
Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. J Immunol (1999) 1.34
CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol (1998) 1.34
Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol (1998) 1.33
Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes. J Immunol (2001) 1.31
Processing and presentation of intact hen egg-white lysozyme by dendritic cells. Eur J Immunol (1992) 1.30
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol (2001) 1.30
Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol (2000) 1.29
Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras. J Exp Med (1994) 1.29
CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol (2000) 1.27
High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation (1998) 1.27
Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev (1994) 1.27
Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J Immunol (2001) 1.26
Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev (1995) 1.26
Gap junctions of chick lens fiber cells. Exp Eye Res (1978) 1.23
Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis (2001) 1.22
Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol (1992) 1.21
IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol (1996) 1.21
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 1.20
Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J Immunol (1997) 1.20
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 1.19
CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev (2001) 1.19
Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev (1993) 1.19
Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol (2000) 1.18
CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol (1996) 1.18
Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J Immunol (1996) 1.17
Phagosomes are fully competent antigen-processing organelles that mediate the formation of peptide:class II MHC complexes. J Immunol (1999) 1.17
ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol (2009) 1.16
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 1.15
HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. J Clin Invest (2001) 1.13
Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the course of experimental allergic encephalomyelitis. J Immunol (2001) 1.13
Square arrays and their role in ridge formation in human lens fibers. J Ultrastruct Res (1984) 1.12
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol (2006) 1.11
B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun (1999) 1.11
Now I know my CpGs. Trends Microbiol (2001) 1.06
NIH conference. Systemic lupus erythematosus. Ann Intern Med (1991) 1.06
Limited T cell response to donor MHC peptides during allograft rejection. Implications for selective immune therapy in transplantation. J Immunol (1994) 1.05
CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun (2000) 1.05
Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol (1999) 1.05
CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol (2003) 1.05
CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol (1999) 1.05
Differential expression of interleukin-2 and gamma interferon in human immunodeficiency virus disease. J Virol (2001) 1.04
Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol (2000) 1.04
Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med (1997) 1.04
Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. Int Immunol (2001) 1.04
Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol (1999) 1.04
CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol (1999) 1.03